Clover Health Investments Appoints Two New Board Directors

What Happened
Clover Health Investments, Corp. (CLOV) announced that on September 22, 2026 its Board appointed Senator Robert G. Torricelli as a Class I director and Dr. Brian J. Miller, M.D., M.B.A., M.P.H., as a Class III director. Senator Torricelli was named to the Board’s Audit Committee and Dr. Miller was named to the Clinical Committee. These appointments fill two previously disclosed vacancies and bring the Board to nine directors. The company attached a press release announcing the appointments as Exhibit 99.1 to the Form 8‑K.

Key Details

• Appointments effective: September 22, 2026.
• New directors: Senator Robert G. Torricelli (Class I) and Dr. Brian J. Miller (Class III).
• Committee assignments: Torricelli → Audit Committee; Miller → Clinical Committee.
• Result: Board increased to nine directors; appointments fill two prior vacancies.
• Filing: 8‑K filed/ amended Sept 25, 2026; press release included as Exhibit 99.1 (title corrected in the amendment).

Why It Matters
Board appointments are governance events investors watch because they affect oversight and strategic guidance. Adding a member to the Audit Committee is relevant for financial oversight and compliance, while adding a physician with medical and public‑health credentials to the Clinical Committee may strengthen clinical oversight for a healthcare-focused company. The filing notes these changes are formalized in the 8‑K and that no other disclosures from the original filing were changed.